Literature DB >> 27154396

Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.

Chit Wai Wong1.   

Abstract

Cholinesterase inhibitors and memantine are the only classes of drugs approved for the treatment of dementia due to Alzheimer's disease. This article provides evidence-based recommendations to address the issues regarding the use of cholinesterase inhibitors and memantine in clinical practice. It includes their efficacy, timing, assessment, use in institutionalized patients, combined use, and use in other dementia types. However, most of the studies are of short duration (<1 year) and are mainly focused on cognitive and global improvement, whereas the practical issue of their use in daily practice such as optimal duration of treatment, long-term efficacy and delaying institutionalization are limited.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27154396     DOI: 10.1007/s40266-016-0372-3

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  73 in total

1.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

Authors:  C Courtney; D Farrell; R Gray; R Hills; L Lynch; E Sellwood; S Edwards; W Hardyman; J Raftery; P Crome; C Lendon; H Shaw; P Bentham
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

Review 2.  Memantine for dementia.

Authors:  R McShane; A Areosa Sastre; N Minakaran
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

3.  Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Adam L Boxer; David S Knopman; Daniel I Kaufer; Murray Grossman; Chiadi Onyike; Neill Graf-Radford; Mario Mendez; Diana Kerwin; Alan Lerner; Chuang-Kuo Wu; Mary Koestler; Jill Shapira; Kathryn Sullivan; Kristen Klepac; Kristine Lipowski; Jerin Ullah; Scott Fields; Joel H Kramer; Jennifer Merrilees; John Neuhaus; M Marsel Mesulam; Bruce L Miller
Journal:  Lancet Neurol       Date:  2013-01-02       Impact factor: 44.182

Review 4.  Systematic review of recent dementia practice guidelines.

Authors:  Jennifer Ngo; Jayna M Holroyd-Leduc
Journal:  Age Ageing       Date:  2014-10-22       Impact factor: 10.668

5.  A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease.

Authors:  Norman R Relkin; William E Reichman; John Orazem; Thomas McRae
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

Review 6.  Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.

Authors:  Jeffrey L Cummings
Journal:  Am J Geriatr Psychiatry       Date:  2003 Mar-Apr       Impact factor: 4.105

7.  Long-term course and effectiveness of combination therapy in Alzheimer disease.

Authors:  Alireza Atri; Lynn W Shaughnessy; Joseph J Locascio; John H Growdon
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703

8.  Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.

Authors:  Sudeep S Gill; Geoffrey M Anderson; Hadas D Fischer; Chaim M Bell; Ping Li; Sharon-Lise T Normand; Paula A Rochon
Journal:  Arch Intern Med       Date:  2009-05-11

9.  Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?

Authors:  A K Wallin; O Hansson; K Blennow; E Londos; L Minthon
Journal:  Int J Geriatr Psychiatry       Date:  2009-06       Impact factor: 3.485

10.  Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?

Authors:  P Murali Doraiswamy; K Ranga Rama Krishnan; Ravi Anand; Hyesung Sohn; Jacquiline Danyluk; Richard D Hartman; Jeffrey Veach
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-05       Impact factor: 5.067

View more
  6 in total

Review 1.  Withdrawal of Antidementia Drugs in Older People: Who, When and How?

Authors:  Carole Parsons
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

2.  Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer's disease.

Authors:  Hai-Yong Liang; Pei-Pei Zhang; Xi-Le Zhang; Yan-Yan Zheng; Yan-Ran Huang; Guo-Qing Zheng; Yan Lin
Journal:  Aging (Albany NY)       Date:  2021-03-03       Impact factor: 5.682

Review 3.  Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer's disease.

Authors:  Madilyn Coles; Genevieve Z Steiner-Lim; Tim Karl
Journal:  Front Neurosci       Date:  2022-09-02       Impact factor: 5.152

4.  Prescribing medications of questionable benefit prior to death: a retrospective study on older nursing home residents with and without dementia in Germany.

Authors:  Christian Rausch; Falk Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  2020-03-26       Impact factor: 2.953

5.  Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer's Disease.

Authors:  Chris J Carter
Journal:  J Alzheimers Dis Rep       Date:  2017-09-28

6.  Monitoring compliance with Clinical Protocol and Therapeutic Guidelines for Alzheimer's disease.

Authors:  Marcela Forgerini; Patrícia de Carvalho Mastroianni
Journal:  Dement Neuropsychol       Date:  2020 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.